ORKA

Oruka Therapeutics, Inc. (ORKA) - Q3 2025 Filing Summary

Business Context and Reporting Period

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. The company operates as a single reportable segment. This summary covers the quarterly period ended September 30, 2025, and the nine months ended September 30, 2025, compared to the period from inception (February 6, 2024) to September 30, 2024.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no product revenue and incurs losses primarily from research and development (R&D) and general and administrative (G&A) expenses.

Material Changes vs. Prior Period

• Financing Activity: In September 2025, the company completed a PIPE financing raising approximately $169.6 million in net proceeds. This significantly bolstered liquidity compared to the prior year.
• Expense Growth: Total operating expenses increased by 16% in Q3 2025 compared to Q3 2024, driven by a 13% increase in R&D expenses and a 36% increase in G&A expenses. R&D expenses rose due to increased personnel costs and stock-based compensation, partially offset by a decrease in external research expenses.
• Interest Income: Interest income surged 188% in Q3 2025 compared to Q3 2024, reflecting higher cash balances and interest rates on marketable securities.
• Related Party Transactions: Related party expenses in R&D decreased in Q3 2025 ($9.6 million) compared to Q3 2024 ($13.5 million), primarily due to the timing of milestone payments and research fees under agreements with Paragon Therapeutics.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($500.9 million) to fund operations for at least twelve months from the filing date.
• Development Pipeline:
  • ORKA-001 (IL-23p19): Phase 1 interim results showed a half-life of ~100 days and sustained inhibition of STAT3 signaling. Phase 2a (EVERLAST-A) dosing commenced in Q3 2025; Phase 2b (EVERLAST-B) is planned for H1 2026.
  • ORKA-002 (IL-17A/F): Phase 1 dosing initiated in Q2 2025; Phase 2 planned for H1 2026.
• Capital Markets: The company entered an At-The-Market (ATM) sales agreement in October 2025 to sell up to $200 million of common stock.
• Risks:
  • Regulatory & Clinical: Risks include failure of clinical trials, delays in regulatory approval, and the unproven nature of half-life extension technology in humans.
  • Third-Party Reliance: Heavy reliance on Paragon Therapeutics for IP and WuXi Biologics for manufacturing. Geopolitical tensions and the potential impact of the BIOSECURE Act on Chinese CMOs are noted risks.
  • Government Shutdowns: Potential disruptions to FDA review processes due to government shutdowns or budget cuts.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $65.6 million operating cash burn over the nine-month period against the $500.9 million cash balance.
• ORKA-001 Phase 2a Data: Monitor the upcoming data readout from the EVERLAST-A trial (expected H2 2026) for efficacy and safety confirmation.
• Manufacturing Supply Chain: Assess the impact of the BIOSECURE Act and tariffs on the company's reliance on WuXi Biologics for clinical and commercial supply.
• Related Party Milestones: Review future milestone payment obligations to Paragon Therapeutics under the License Agreements (up to $12M clinical and $10M regulatory per program).
• Dilution Risk: Evaluate the potential dilution from the ATM facility and future financing needs given the lack of revenue.